8-K: Dyadic International Secures $6 Million in Convertible Notes to Fuel Growth

Dyadic International has raised $6 million through a private placement of convertible notes to accelerate revenue growth and commercialization efforts.

Summary

• Dyadic International has entered into a securities purchase agreement to issue $6 million in senior secured convertible promissory notes due March 8, 2027.
• The notes were sold in a private placement to family members and trusts related to CEO Mark Emalfarb.
• The net proceeds from the sale, estimated at $5.85 million after expenses, will be used for working capital and general corporate purposes.
• The convertible notes carry an 8% annual interest rate, payable quarterly in cash, and are secured by a first priority lien on substantially all assets of the company and its subsidiary.
• The notes can be converted into common stock at the holder's option, with an initial conversion price of $1.79 per share, subject to certain adjustments.
• The company cannot issue more than 19.99% of its outstanding common stock upon conversion of the notes, or breach Nasdaq regulations.
• Holders have the option to require the company to redeem the notes on specific dates, and the company also has the option to redeem the notes on those dates.
• The notes include customary terms, covenants, and events of default, with an 18% interest rate applied after an event of default.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful capital raise and future growth prospects. However, the secured nature of the debt and potential dilution are factors that temper the overall sentiment.

Positives

• The $6 million capital injection provides Dyadic with additional working capital to support its operations and growth initiatives.
• The conversion feature of the notes could potentially lead to increased equity and reduced debt for the company in the future.
• The private placement demonstrates confidence in the company from insiders, including the CEO's family.
• The funds are intended to accelerate near-term revenue growth and commercialization of Dyadic's technologies.

Negatives

• The notes are secured by a first priority lien on substantially all assets, which could limit the company's flexibility in the future.
• The 8% interest rate represents a cost of capital for the company.
• The potential conversion of the notes could dilute existing shareholders if the share price increases.
• The 18% interest rate after an event of default is a significant penalty.

Risks

• The company's ability to meet its obligations under the notes is dependent on its future financial performance.
• The conversion of the notes could be limited by the 19.99% cap on the issuance of new shares.
• The company may face challenges in achieving its revenue growth and commercialization goals.
• The company is subject to customary terms, covenants, and events of default, which could trigger acceleration of the debt.

Future Outlook

Dyadic anticipates reaching multiple revenue streams and other inflection points within the next two years through fully funded collaborations and the company's pipeline products. They also plan to expand the use of the Dapibus platform for developing alternative recombinant proteins.

Management Comments

• This private placement funding is pivotal for Dyadic in propelling our near-term revenue growth and expediting what we believe will be the global adoption and commercialization of Dyadic technologies, particularly the C1 and Dapibus protein production platforms, across pharmaceutical and non-pharmaceutical sectors, said Mr. Emalfarb, Dyadics President and CEO.
• Within the next two years, we anticipate reaching multiple revenue streams and other inflection points through fully funded collaborations and the Companys pipeline products to enhance shareholder value.
• We believe the top-line safety and reactogenicity results for Dyadics first in human clinical trial is transformational because we successfully demonstrated for the first time that a protein manufactured using our C1 technology platform is safe for use in humans.
• I cannot overstate how exciting this time is in Dyadics history. We are uniquely positioned to rapidly capitalize on the present opportunities and those on the horizon.

Industry Context

This announcement comes as the biotechnology industry is experiencing increased demand for innovative protein production platforms. Dyadic's focus on microbial platforms aligns with the trend towards more efficient and scalable biomanufacturing processes. The company's emphasis on both pharmaceutical and non-pharmaceutical applications positions it to capitalize on diverse market opportunities.

Comparison to Industry Standards

• The 8% interest rate on the convertible notes is within the typical range for secured debt financing in the biotech sector, but may be considered high for a company with established revenue streams.
• The conversion price of $1.79 per share represents a premium over the recent trading price, which is common in convertible note offerings to incentivize investors.
• The use of a first priority lien on substantially all assets is a standard practice for secured debt financing, but it can limit the company's financial flexibility.
• The company's focus on C1 and Dapibus platforms is comparable to other biotech companies developing novel protein production technologies, such as Amyris and Ginkgo Bioworks, but Dyadic's focus on fungal-based platforms is a differentiator.
• The company's stated goal of reaching multiple revenue streams within two years is ambitious but achievable given the current market demand for biomanufacturing solutions.

Related Party Transactions

• The purchasers of the convertible notes include immediate family members and family trusts related to Mark Emalfarb, the company's President and CEO.

Stakeholder Impact

• Shareholders may experience dilution if the convertible notes are converted into common stock.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Customers and partners may see accelerated development and commercialization of Dyadic's technologies.
• Creditors may be impacted by the first priority lien on substantially all assets.

Next Steps

• Dyadic intends to use the net proceeds for working capital and general corporate purposes.
• The company will continue to pursue collaborations and commercialization of its C1 and Dapibus platforms.
• Dyadic will work to achieve multiple revenue streams and other inflection points within the next two years.

Key Dates

Keywords

convertible notes, private placement, secured debt, working capital, biotechnology, protein production, C1 technology, Dapibus platform, biopharmaceutical, Mark Emalfarb